1. Home
  2. ALT vs AMBQ Comparison

ALT vs AMBQ Comparison

Compare ALT & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • AMBQ
  • Stock Information
  • Founded
  • ALT 1997
  • AMBQ 2010
  • Country
  • ALT United States
  • AMBQ United States
  • Employees
  • ALT 59
  • AMBQ N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • AMBQ Semiconductors
  • Sector
  • ALT Health Care
  • AMBQ Technology
  • Exchange
  • ALT Nasdaq
  • AMBQ Nasdaq
  • Market Cap
  • ALT 501.9M
  • AMBQ 451.6M
  • IPO Year
  • ALT N/A
  • AMBQ 2025
  • Fundamental
  • Price
  • ALT $4.86
  • AMBQ $23.72
  • Analyst Decision
  • ALT Strong Buy
  • AMBQ Buy
  • Analyst Count
  • ALT 7
  • AMBQ 4
  • Target Price
  • ALT $16.33
  • AMBQ $41.75
  • AVG Volume (30 Days)
  • ALT 3.2M
  • AMBQ 98.1K
  • Earning Date
  • ALT 11-06-2025
  • AMBQ 11-06-2025
  • Dividend Yield
  • ALT N/A
  • AMBQ N/A
  • EPS Growth
  • ALT N/A
  • AMBQ N/A
  • EPS
  • ALT N/A
  • AMBQ N/A
  • Revenue
  • ALT $20,000.00
  • AMBQ $72,109,000.00
  • Revenue This Year
  • ALT N/A
  • AMBQ N/A
  • Revenue Next Year
  • ALT N/A
  • AMBQ $25.34
  • P/E Ratio
  • ALT N/A
  • AMBQ N/A
  • Revenue Growth
  • ALT N/A
  • AMBQ 10.03
  • 52 Week Low
  • ALT $2.90
  • AMBQ $22.12
  • 52 Week High
  • ALT $10.88
  • AMBQ $51.76
  • Technical
  • Relative Strength Index (RSI)
  • ALT 68.61
  • AMBQ N/A
  • Support Level
  • ALT $4.40
  • AMBQ N/A
  • Resistance Level
  • ALT $4.75
  • AMBQ N/A
  • Average True Range (ATR)
  • ALT 0.29
  • AMBQ 0.00
  • MACD
  • ALT 0.07
  • AMBQ 0.00
  • Stochastic Oscillator
  • ALT 95.22
  • AMBQ 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About AMBQ Ambiq Micro Inc. Common Stock

Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.

Share on Social Networks: